Results 131 to 140 of about 5,403 (175)
Some of the next articles are maybe not open access.
Radioimmunotherapy of brain tumor
Neurological Research, 2006Despite years of intensive research, the prognosis of high-grade gliomas (HGG) remains poor, as these tumors are highly resistant to currently available therapies. Therefore, there is a need for the development of new therapeutic strategies, such as the use of monoclonal antibodies (MoAbs) in association with radioisotopes, in order to achieve better ...
Giovanni Paganelli +2 more
exaly +3 more sources
Abscopal effect in radioimmunotherapy
International Immunopharmacology, 2020Abscopal effect is an interesting phenomenon in radiobiology that causes activation of immune system against cancer cells. Traditionally, this phenomenon was known as a suppressor of non-irradiated tumors or metastasis. However, it can be used as a stimulator of the immune system against primary tumor during radiotherapy.
Milad, Ashrafizadeh +5 more
openaire +2 more sources
Radioimmunotherapy of lymphoma
1993The development of radiolabeled monoclonal antibodies (MoAb) was a significant advance in the use of these molecules for the treatment of human neoplasms. Unlabeled murine MoAbs had proven to have modest activity against human neoplasms due to (1) the relatively poor interactions between the antibody Fc receptors and human effector cells, and (2) the ...
T M, Kuzel, S T, Rosen
openaire +2 more sources
Fundamentals of radioimmunotherapy
International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1991Design of a radioimmunotherapy trial is a complex process. This involves antibody selection, choice of radioisotope, and labeling method. Observation of the behavior of the new radiopharmaceutical involves determination of normal organ and tumor uptake, as well as residence time.
openaire +2 more sources
Review of clinical radioimmunotherapy
Expert Review of Anticancer Therapy, 2006Radioimmunotherapy involves a form of biologically targeted radiopharmaceutical treatment in which a radioactive isotope (typically a short-range, high-energy beta-emitter) is chemically bound to a target-specific monoclonal antibody or fragment. Thus, these radioimmunoconjugates combine the exquisite targeting specificity of the humoral immune system ...
John W Sweetenham, Roger M Macklis
exaly +3 more sources
Radioimmunotherapy for lymphoma
Current Opinion in Oncology, 1999After more than a decade of unfulfilled promises, radioimmunotherapy for the treatment of non-Hodgkin's lymphoma has been demonstrated to be efficacious in the treatment of refractory disease. It is likely that in the near future, the Food and Drug Administration will approve one or more radioimmunoconjugates for clinical use.
openaire +2 more sources
Experimental radioimmunotherapy
Seminars in Radiation Oncology, 2000Experimental radioimmunotherapy (RIT) studies in animal models have contributed significantly to the design of clinical RIT protocols, although the results have not always been directly translated. Reviewed in this article are current areas of active research in experimental RIT to increase the therapeutic ratio that are likely to have a significant ...
openaire +2 more sources
Radioimmunotherapy for Peritoneal Cancers
Immunotherapy, 2013Peritoneal carcinomatosis is the most common secondary cancerous disease to affect the peritoneal cavity, implying poor prognosis. Standard therapy consists of cytoreductive surgery in combination with adjuvant chemotherapy. To improve the therapeutic outcome, targeted therapy using radionuclides such as α-, β- and Auger emitters coupled to antibodies ...
Christof, Seidl, Markus, Essler
openaire +2 more sources
Selection of radionuclides for radioimmunotherapy
Medical Physics, 1993Selection criteria for radionuclides to be used in radioimmunotherapy are reviewed. Among the topics covered are half‐life, specific activity, type of emission, and ease of preparation. (AIP)
L F, Mausner, S C, Srivastava
openaire +2 more sources
Breast Disease, 2000
HER2/neu is a receptor protein whose overexpression strongly correlates with poor prognosis in breast carcinomas. It is used increasingly as a therapeutic target for breast carcinomas in clinical human trials. In particular, monoclonal antibodies (mAbs) that target HER2/neu have been investigated for therapeutic applications.
M W, Brechbiel, T A, Waldmann
openaire +2 more sources
HER2/neu is a receptor protein whose overexpression strongly correlates with poor prognosis in breast carcinomas. It is used increasingly as a therapeutic target for breast carcinomas in clinical human trials. In particular, monoclonal antibodies (mAbs) that target HER2/neu have been investigated for therapeutic applications.
M W, Brechbiel, T A, Waldmann
openaire +2 more sources